X
Record #46041

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

Publisher
Elsevier
Original paper date
Aug 5, 2022
Institution
Department of Dermatology, Skin Cancer Center, University Hospital Zurich, Zurich, Switzerland · IRCCS Istituto Europeo di Oncologia, Milan, Italy · F Hoffman-La Roche, Basel, Switzerland · Hospital de Clínicas de Porto Alegre, Unidade de Pesquisa Clinica em Oncologia, Porto Alegre, Brazil · Gustave Roussy and Université Paris-Saclay, Villejuif-Paris, France · Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy · Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy · IRCCS Ospedale Policlinico San Martino, Genova, Italy · Onkologikoa Hospital, Donostia, Spain · Országos Onkológiai Intézet, Budapest, Hungary · Hospital Universitario Virgen Macarena, Clinical Oncology Department and Medicine Department, University of Seville, Seville, Spain · Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Open access
No
Article type
Research Article
Broad categories
(BLS) Biology - Cancer(HSC) Medicine - Oncology(HSC) Medicine - Pharmacology
Notes from Retraction Watch

see https://www.sciencedirect.com/science/article/pii/S1470204523003340; see also: https://www.sciencedirect.com/science/article/pii/S1470204523002929;

Citation lifecycle

How this paper is being cited

Pre-retraction
14
Same day
0
Post-retraction
20
% post-retraction
58.8%
~14.9 citations/yr before retraction · ~6.3 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse